Exploiting CD38-mediated endocytosis for immunoliposome internalization

Anti-Cancer Drugs

Volumn 19, Issue 6, 2008, Pages 599-605

  Orciani, Monia ^a   Cavaletti, Guido ^c   Fino, Vincenzo ^b   Mattioli Belmonte, Monica ^a   Tredici, Giovanni ^c   Bruni, Paolo ^b   Di Primio, Roberto ^a,b  

^a Department of Molecular Pathology and Innovative Therapies   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antibody therapy; CD38; Immunoliposome

Indexed keywords

6 CARBOXYFLUORESCEIN; CD38 ANTIGEN; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IB4; PHOSPHOLIPID; STREPTAVIDIN; UNCLASSIFIED DRUG; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; BIOTINYLATION; CELL FUNCTION; CONTROLLED STUDY; CYTOFLUOROMETRY; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; CELL STRAIN K 562; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; BIOTINYLATION; ENDOCYTOSIS; HUMANS; K562 CELLS; LIPOSOMES; MEMBRANE GLYCOPROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 53749100273     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282ffd673     Document Type: Article

References (22)

1. Huang S, Terstappen LWMM. Lymphoid and myeloid differentiation of single human CD34 + , HLA-Dr +, CD38- hematopoietic stem cells. Blood 1994; 83:1515-1526.
2. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990; 144:2811-2815.
3. Terstappen LW, Safford M, Unterhalt M, Könemann S, Zurlutter K, Piechotka K, et al.Flow cytometric characterization of acute myeloid leukemia: IV: comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6:993-1000.
4. Zupo S, Massara R, Dono M, Rossi E, Malavasi F, Cosulich ME, et al.Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000; 95:1199-1206.
5. Funaro A, Reinis M, Trubiani O, Santi S, Di Primio R, Malavasi F. CD38 functions are regulated through an internalization step. J Immunol 1998; 160:2238-2247.
6. Trubiani O, Guarnieri S, Orciani M, Salvolini E, Di Primio R. Sphingolipid microdomains mediate CD38 internalization: topography of the endocytosis. Int J Immunopathol Pharmacol 2004; 17:293-300.
7. Stevenson GT. CD38 as a therapeutic target. Mol Med 2006; 12:345-346.
8. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ, et al.Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155:925-937.
9. Gregoriadis G, Senior J, Wolff B, Kirby C. Targeting of liposomes to accessible cells in vivo. Ann N Y Acad Sci 1985; 446:319-340.
10. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Mattay K, Huang SK, et al.Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88:11460-11464.
11. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-14169.
12. Schnyder A, Krähenbühl S, Tö rök M, Drewe J, Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 2004; 377:61-67.
13. Knoll G, Burger KN, Bron R, van Meer G, Verkleij AJ. Fusion of liposomes with the plasma membrane of epithelial cells: fate of incorporated lipids as followed by freeze fracture and autoradiography of plastic sections. J Cell Biol 1988; 107:2511-2521.
14. Trubiani O, Guarnieri S, Eleuterio E, Di Giuseppe F, Orciani M, Angelucci S, et al.Insights into nuclear localization and dynamic association of CD38 in Raji and K562 cells. J Cell Biochem 2008; 103:1294-1308.
15. Stevenson FK, George AJT, Glennie MJ. Anti-idiotypic therapy of leukemias and lymphomas. Chem Immuno 1990; 148:126-166.
16. Eisenthal A, Cameron RB, Rosenberg SA. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 1990; 144: 4463-4471.
17. Hellstrom I, Brankovan V, Hellstrom KE. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 1985; 82:1499-1502.
18. Stevenson GT, Glennie MJ. Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target. Cancer Sum 1985; 4:213-244.
19. Stevenson GT, Glennie MJ, Paul FE, Stevenson FK, Watts HF, Wyeth P. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells. Biosci Rep 1985; 5:991-998.
20. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-327.
21. Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry. Blood 1990; 76:1739-1747.
22. Kinniburgh D, Russell NH. Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant 1993; 12:489-494.